Login Register Cart 0
Generic placeholder image

Current Organic Synthesis

Editor-in-Chief

ISSN (Print): 1570-1794
ISSN (Online): 1875-6271

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

Recent Advances in the Synthesis and Biological Activities of Quinolactacin and its Derivatives: A Comprehensive Review

Author(s): Noor Hidayah Pungot*, Siti Wadhihah Athirah Ab Rahman, Nuriyah Izzati Syafawi, Putri Nur Arina Mohd Ariff, Siti Zafirah Binti Zulkifli and Aimi Suhaily Saaidin

Volume 22, Issue 8, 2025

Published on: 06 August, 2025

Page: [883 - 896] Pages: 14

DOI: 10.2174/0115701794378020250717163142

Price: $65

Abstract

In recent years, quinolactacins and their derivatives have attracted significant research attention due to their distinctive structural features and intriguing biological properties. These heterocyclic compounds have emerged as promising candidates in medicinal chemistry due to their broad spectrum of therapeutic activities. This review article provides a comprehensive study on recent progress in synthesising and investigating the biological properties of quinolactacins and their diverse analogues, offering insights into the diverse synthetic strategies that have been explored to enhance the efficiency and scalability of their production. The primary emphasis lies on the biological activities exhibited by quinolactacins, including their notable anti-bacterial efficacies, anti-cancer, anti-proliferative, anti-oxidant, anti-malarial, and anti-viral. These compounds have shown great potential as therapeutic agents in the fight against various infectious diseases and cancers, making them promising candidates for drug development. Moreover, this study sheds light on the latest endeavours aimed for the synthesis of quinolactacins and their derivatives. This study serves as a valuable resource for researchers who aim to investigate and further harness the therapeutic potential of quinolactacins and their derivatives in the battle against life-threatening diseases, paving the way for future breakthroughs in drug development.

Keywords: Biological activities, quinolactacin, synthesis route, anti-cancer, anti-bacterial, anti-viral, heterocyclic compounds.

Next »
Graphical Abstract

[1]
Atanasov, A.G.; Zotchev, S.B.; Dirsch, V.M.; Orhan, I.E.; Banach, M.; Rollinger, J.M.; Barreca, D.; Weckwerth, W.; Bauer, R.; Bayer, E.A.; Majeed, M.; Bishayee, A.; Bochkov, V.; Bonn, G.K.; Braidy, N.; Bucar, F.; Cifuentes, A.; D’Onofrio, G.; Bodkin, M.; Diederich, M.; Dinkova-Kostova, A.T.; Efferth, T.; El Bairi, K.; Arkells, N.; Fan, T-P.; Fiebich, B.L.; Freissmuth, M.; Georgiev, M.I.; Gibbons, S.; Godfrey, K.M.; Gruber, C.W.; Heer, J.; Huber, L.A.; Ibanez, E.; Kijjoa, A.; Kiss, A.K.; Lu, A.; Macias, F.A.; Miller, M.J.S.; Mocan, A.; Müller, R.; Nicoletti, F.; Perry, G.; Pittalà, V.; Rastrelli, L.; Ristow, M.; Russo, G.L.; Silva, A.S.; Schuster, D.; Sheridan, H.; Skalicka-Woźniak, K.; Skaltsounis, L.; Sobarzo-Sánchez, E.; Bredt, D.S.; Stuppner, H.; Sureda, A.; Tzvetkov, N.T.; Vacca, R.A.; Aggarwal, B.B.; Battino, M.; Giampieri, F.; Wink, M.; Wolfender, J-L.; Xiao, J.; Yeung, A.W.K.; Lizard, G.; Popp, M.A.; Heinrich, M.; Berindan-Neagoe, I.; Stadler, M.; Daglia, M.; Verpoorte, R.; Supuran, C.T. Natural products in drug discovery: Advances and opportunities. Nat. Rev. Drug Discov., 2021, 20(3), 200-216.
[http://dx.doi.org/10.1038/s41573-020-00114-z] [PMID: 33510482]
[2]
Li, G.; Lou, H.X. Strategies to diversify natural products for drug discovery. Med. Res. Rev., 2018, 38(4), 1255-1294.
[http://dx.doi.org/10.1002/med.21474] [PMID: 29064108]
[3]
Louie, K.B.; Kosina, S.M.; Hu, Y.; Otani, H.; de Raad, M.; Kuftin, A.N. Mass spectrometry for natural product discovery. Comprehensive Nat. Prod, 2020, III, 263-306.
[4]
Chapter 12. Stud Nat. Prod Chem., 2019, 62, 433-453.
[5]
Park, S.J.; Cho, K.N.; Kim, W.G.; Lee, K.I. An expedient synthesis of (+)-quinolactacin A2. Tetrahedron Lett., 2004, 45(48), 8793-8795.
[http://dx.doi.org/10.1016/j.tetlet.2004.10.001]
[6]
Li, P.; Lu, H.; Zhang, Y.; Zhang, X.; Liu, L.; Wang, M.; Liu, L. The natural products discovered in marine sponge-associated microorganisms: Structures, activities, and mining strategy. Front. Mar. Sci., 2023, 10, 1191858.
[http://dx.doi.org/10.3389/fmars.2023.1191858]
[7]
Kakinuma, N.; Iwai, H.; Takahashi, S.; Hamano, K.; Yanagisawa, T.; Nagai, K.; Tanaka, K.; Suzuki, K.; Kirikae, F.; Kirikae, T.; Nakagawa, A.; Quinolactacins, A. B and C: Novel quinolone compounds from Penicillium sp. EPF-6. I. Taxonomy, production, isolation and biological properties. J. Antibiot., 2000, 53(11), 1247-1251.
[http://dx.doi.org/10.7164/antibiotics.53.1247] [PMID: 11213284]
[8]
Sasaki, T.; Takahashi, S.; Uchida, K.; Funayama, S.; Kainosho, M.; Nakagawa, A. Biosynthesis of quinolactacin A, a TNF production inhibitor. J. Antibiot., 2006, 59(7), 418-427.
[http://dx.doi.org/10.1038/ja.2006.59] [PMID: 17025018]
[9]
Lu, L.; Hu, W.; Tian, Z.; Yuan, D.; Yi, G.; Zhou, Y.; Cheng, Q.; Zhu, J.; Li, M. Developing natural products as potential anti-biofilm agents. Chin. Med., 2019, 14(1), 11.
[http://dx.doi.org/10.1186/s13020-019-0232-2] [PMID: 30936939]
[10]
Zhu, J.; Lu, Y.; Chen, J.; Chen, J.; Zhang, H.; Bao, X.; Ye, X.; Wang, H. Total synthesis of quinolactacin-H from marine-derived Penicillium sp. ENP701 and biological activities. RSC Advances, 2020, 10(41), 24251-24254.
[http://dx.doi.org/10.1039/D0RA05244B] [PMID: 35516178]
[11]
Kim, W.G.; Song, N.K.; Yoo Quinolactacins, I.D. A1, A2, B1, B2, C1, and C2, novel quinolone alkaloids from Penicillium citrinum. J. Antibiot., 1980, 33, 831-835.
[12]
M Heravi, M.; Zadsirjan, V.; Malmir, M. Application of the asymmetric pictet-spengler reaction in the total synthesis of natural products and relevant biologically active compounds. Molecules, 2018, 23(4), 943.
[http://dx.doi.org/10.3390/molecules23040943] [PMID: 29670061]
[13]
Tatsuta, K.; Misawa, H.; Chikauchi, K. Biomimetic total synthesis of quinolactacin B, TNF production inhibitor, and its analogs. J. Antibiot., 2001, 54(1), 109-112.
[http://dx.doi.org/10.7164/antibiotics.54.109] [PMID: 11269706]
[14]
Zhang, X.; Jiang, W.; Sui, Z. Concise enantioselective syntheses of quinolactacins A and B through alternative Winterfeldt oxidation. J. Org. Chem., 2003, 68(11), 4523-4526.
[http://dx.doi.org/10.1021/jo020746a] [PMID: 12762761]
[15]
Karolina, P. Pictet-Spengler reactions for the synthesis of pharmaceutically relevant heterocycles. Curr. Opinion in Drug Disc. &. Develop, 2010, 13(6), 669-684.
[16]
Waldmann, H.; Schmidt, G.; Henke, H.; Burkard, M. Asymmetric pictet-spengler reactions employing n, n-phthaloyl amino acids as chiral auxiliary groups. Angew. Chem. Int. Ed. Engl., 1995, 34(21), 2402-2403.
[http://dx.doi.org/10.1002/anie.199524021]
[17]
Petersen, R.G.; Komnatnyy, V.V.; Nielsen, T.E. Synthesis of constrained peptidomimetics via the Pictet Spengler reaction. Top. Heterocycl. Chem., 2017, 49, 81-103.
[http://dx.doi.org/10.1007/7081_2015_190]
[18]
Li-Na, W.; Su-Li, S.; Jin, Qu. Simple and efficient synthesis of tetrahydro-β-carbolines via the Pictet-Spengler reaction in 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP). RSC Advances, 2020, 10, 24251-24254.
[19]
Ashari, N.A.N.; Pungot, N.H.; Jani, N.A.; Shaameri, Z. Efficient synthesis of novel 1-substituted β-carboline derivatives via pictet-spengler cyclization of 5-hydroxy-L-tryptophan. Malaysian. J. Fund. Appl. Sci., 2022, 18(2), 218-226.
[http://dx.doi.org/10.11113/mjfas.v18n2.2331]
[20]
Ash’ari, N.A.N.; Shaameri, Z.; Pungot, N.H.; Jani, N.A. Facile synthesis of n-alkylated daibucarboline A derivatives via pictet-spengler condensation of tryptamine. Sci., 2021, 25(5), 706-715.
[21]
Abe, M.; Imai, T.; Ishii, N.; Usui, M. Synthesis of quinolactacide via an acyl migration reaction and dehydrogenation with manganese dioxide, and its insecticidal activities. Biosci. Biotechnol. Biochem., 2006, 70(1), 303-306.
[http://dx.doi.org/10.1271/bbb.70.303] [PMID: 16428857]
[22]
Alvaro, M.; Baldoví, V.; García, H.; Miranda, M.A.; Primoa, J. A novel photochemical 1,4-acyl migration in enol esters. The photolysis of enol acetates of 3-phenylpropiophenones. Tetrahedron Lett., 1987, 28(31), 3613-3614.
[http://dx.doi.org/10.1016/S0040-4039(00)95549-7]
[23]
Shankaraiah, N.; da Silva, W.A.; Andrade, C.K.Z.; Santos, L.S. Enantioselective total synthesis of (S)-(−)-quinolactacin B. Tetrahedron Lett., 2008, 49(27), 4289-4291.
[http://dx.doi.org/10.1016/j.tetlet.2008.04.130]
[24]
Uematsu, N.; Fujii, A.; Hashiguchi, S.; Ikariya, T.; Noyori, R. Asymmetric transfer hydrogenation of imines. J. Am. Chem. Soc., 1996, 118(20), 4916-4917.
[http://dx.doi.org/10.1021/ja960364k]
[25]
Yamakawa, M.; Ito, H.; Noyori, R. Mechanism of asymmetric transfer hydrogenation of ketones catalyzed by chiral η6-arene–ruthenium(II) complexes. J. Am. Chem. Soc., 2000, 122(7), 1466-1478.
[http://dx.doi.org/10.1021/ja991638h]
[26]
Santos, L.S.; Pilli, R.A.; Rawal, V.H. Enantioselective total syntheses of (+)-arborescidine A, (-)-arborescidine B, and (-)-arborescidine C. J. Org. Chem., 2004, 69(4), 1283-1289.
[http://dx.doi.org/10.1021/jo035165f] [PMID: 14961682]
[27]
Majid, M.; Heravi, S.K.; Niousha, N. Bischler-Napieralski reaction in the syntheses of isoquinolines. Adv. Heterocycl. Chem., 2014, 112, 143-172.
[28]
da Silva, G.; Moreira, R.; Silva, A.M.S. Chapter 12 - Bioactive quinolactacins and structurally related pyrroloquinolones. Studi Nat. Prod Chem., 2019, 62, 433-453.
[http://dx.doi.org/10.1016/B978-0-444-64185-4.00012-5]
[29]
Machtey, V.; Gottlieb, H.E.; Byk, G. Total synthesis of structures proposed for quinocitrinines A and B and their analogs. Microwave energy as efficient tool for generating heterocycles. ARKIVOC, 2011, 2011(9), 308-324.
[http://dx.doi.org/10.3998/ark.5550190.0012.923]
[30]
Kulkarni, P.P.; Kadam, A.J.; Mane, R.B.; Desai, U.V.; Wadgaonkar, P.P. Demethylation of methyl aryl ethers using pyridine hydrochloride in solvent-free conditions under microwave irradiation. J. Chem. Res., 1999, 394-395.
[31]
Saito, K.; Yoshida, M.; Uekusa, H.; Doi, T. Facile synthesis of pyrrolyl 4-quinolinone alkaloid quinolactacide by 9-AJ-catalyzed tandem acyl transfer-cyclization of O-alkynoylaniline derivatives. ACS Omega, 2017, 2(8), 4370-4381.
[http://dx.doi.org/10.1021/acsomega.7b00793] [PMID: 31457730]
[32]
Nagy, A.; Novák, Z.; Kotschy, A. Sequential and domino Sonogashira coupling: Efficient tools for the synthesis of diarylalkynes. J. Organomet. Chem., 2005, 690(20), 4453-4461.
[http://dx.doi.org/10.1016/j.jorganchem.2004.12.036]
[33]
Sonogashira coupling 2021. Available from: https://www.organic-chemistry.org/namedreactions/sonogashira-coupling.shtm
[34]
Jacobsen, E.N. Total synthesis of quinolactacin and its biological evaluation. J. Am. Chem. Soc., 2004, 126, 14869-14870.
[35]
Scharf, M.J.; List, B. A catalytic asymmetric pictet-spengler platform as a biomimetic diversification strategy toward naturally occurring alkaloids. J. Am. Chem. Soc., 2022, 144(34), 15451-15456.
[http://dx.doi.org/10.1021/jacs.2c06664] [PMID: 35976162]
[36]
Andres, R.; Wang, Q.; Zhu, J. Catalytic enantioselective Pictet–Spengler reaction of α-Ketoamides catalyzed by a single H-bond donor organocatalyst. Angew. Chem. Int. Ed., 2022, 61(19), 202201788.
[http://dx.doi.org/10.1002/anie.202201788] [PMID: 35225416]
[37]
Ismail, A.Z.H.; Mohd Arif, P.N.A.; Rezali, N.S.; Mohammat, M.F.; Shaameri, Z. Synthetic approaches towards quinolactacin derivatives via diels-alder, acyl migration and multicomponent reactions. Malays. J. Anal. Sci., 2022, 26, 755-765.
[38]
Caplar, V. Total synthesis of quinolactacin and its biological activities. J. Org. Chem., 2003, 68, 5213-5215.
[39]
Zholdassov, Y.S.; Yuan, L.; Garcia, S.R.; Kwok, R.W.; Boscoboinik, A.; Valles, D.J.; Marianski, M.; Martini, A.; Carpick, R.W.; Braunschweig, A.B. Acceleration of Diels-Alder reactions by mechanical distortion. Science, 2023, 380(6649), 1053-1058.
[http://dx.doi.org/10.1126/science.adf5273] [PMID: 37289895]
[40]
Yuan, Y.; Li, X.; Ding, K. Acid-free aza diels-alder reaction of danishefsky’s diene with imines. Org. Lett., 2002, 4(19), 3309-3311.
[http://dx.doi.org/10.1021/ol0265822] [PMID: 12227776]
[41]
Patel, D.B.; Parmar, J.A.; Patel, S.S.; Naik, U.J.; Patel, H.D. Recent advances in ester synthesis by Multi-Component Reactions (MCRs): A Review. Curr. Org. Chem., 2021, 25(5), 539-553.
[http://dx.doi.org/10.2174/1385272825666210111111805]
[42]
Thai, T.; Salisbury, B.H.; Zito, P.M. Ciprofloxacin, 2023.
[43]
Pham, T.D.M.; Ziora, Z.M.; Blaskovich, M.A.T. Quinolone antibiotics. MedChemComm, 2019, 10(10), 1719-1739.
[http://dx.doi.org/10.1039/C9MD00120D] [PMID: 31803393]
[44]
Doble, A. Nalidixic acid. X Pharm. The Compr Pharmacol. Ref, 2007, 1-5.
[45]
Paton, J.H.; Reeves, D.S. Fluoroquinolone antibiotics. Drugs, 1988, 36(2), 193-228.
[http://dx.doi.org/10.2165/00003495-198836020-00004] [PMID: 3053126]
[46]
What is cancer? 2023. Available from: https://www.cancer.gov/about-cancer/understanding/what-is-cancer
[47]
Cancer. 2023. Available from: https://www.who.int/health-topics/cancer#tab=tab_1
[48]
Cancer - NHS 2023. Available from: https://www.nhs.uk/conditions/cancer/
[49]
What is cancer? cancer.net. 2023. Available from: https://www.cancer.net/navigating-cancer-care/cancer-basics/what-cancer
[50]
Kloskowski, T.; Frąckowiak, S.; Adamowicz, J.; Szeliski, K.; Rasmus, M.; Drewa, T.; Pokrywczyńska, M. Quinolones as a potential drug in genitourinary cancer treatment-a literature review. Front. Oncol., 2022, 12, 890337.
[http://dx.doi.org/10.3389/fonc.2022.890337] [PMID: 35756639]
[51]
Yadav, V.; Talwar, P. Repositioning of fluoroquinolones from antibiotic to anti-cancer agents: An underestimated truth. Biomed. Pharmacother., 2019, 111, 934-946.
[http://dx.doi.org/10.1016/j.biopha.2018.12.119] [PMID: 30841473]
[52]
Kloskowski, T.; Szeliski, K.; Fekner, Z.; Rasmus, M.; Dąbrowski, P.; Wolska, A.; Siedlecka, N.; Adamowicz, J.; Drewa, T.; Pokrywczyńska, M. Ciprofloxacin and levofloxacin as potential drugs in genitourinary cancer treatment-the effect of dose–response on 2D and 3D cell cultures. Int. J. Mol. Sci., 2021, 22(21), 11970.
[http://dx.doi.org/10.3390/ijms222111970] [PMID: 34769400]
[53]
Hawtin, R.E.; Stockett, D.E.; Byl, J.A.W.; McDowell, R.S.; Tan, N.; Arkin, M.R.; Conroy, A.; Yang, W.; Osheroff, N.; Fox, J.A. Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II. PLoS One, 2010, 5(4), 10186.
[http://dx.doi.org/10.1371/journal.pone.0010186] [PMID: 20419121]
[54]
Scatena, C.D.; Kumer, J.L.; Arbitrario, J.P.; Howlett, A.R.; Hawtin, R.E.; Fox, J.A.; Silverman, J.A. Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo. Cancer Chemother. Pharmacol., 2010, 66(5), 881-888.
[http://dx.doi.org/10.1007/s00280-009-1234-z] [PMID: 20058009]
[55]
Zhao, F.; Liu, Z.; Yang, S.; Ding, N.; Gao, X. Quinolactacin biosynthesis involves non-ribosomal-peptide-synthetase-catalyzed Dieckmann condensation to form the quinolone-γ-lactam hybrid. Angew. Chem. Int. Ed., 2020, 59(43), 19108-19114.
[http://dx.doi.org/10.1002/anie.202005770] [PMID: 32663343]
[56]
Kyeremeh, K.; Owusu, K.B.; Ofosuhene, M.; Ohashi, M.; Agyapong, J.; Camas, A.S.; Mustafa Camas, M. Anti-proliferative and anti-plasmodial activity of quinolactacin A2, citrinadin a and butrecitrinadin co-isolated from a ghanaian mangrove endophytic fungus cladosporium oxysporum strain BRS2A-AR2F. Journal of chemistry and applications, 2017, 3(1), 01-12.
[http://dx.doi.org/10.13188/2380-5021.1000007]
[57]
Kyeremeh, K. Isolation of quinolactacin derivatives from Cladosporium oxysporum and their biological activities. J. Chem. Pharm. Res., 2017, 9(3), 41-48.
[58]
Citrinadin A and butrecitrinadin co-isolated from a ghanaian mangrove endophytic fungus cladosporium oxysporum strain BRS2AAR2F. 2023. Available from: https://www.researchgate.net/ publication/319230669_Anti-Proliferative_and_Anti-Plasmodia_Activity_of_ Quinolactacin_ A2_ Citrinadin_ A_and_Butrecitrinadin_coisolated_from_a_Ghanaian_Mangrove_Endophytic_ Fungus_Cladosporium_oxysporum_strain_BRS2A-AR2F
[59]
Meiyanto, E.; Putri, H.; Arum Larasati, Y.; Yudi Utomo, R.; Istighfari Jenie, R.; Ikawati, M.; Lestari, B.; Yoneda-Kato, N.; Nakamae, I.; Kawaichi, M.; Kato, J.Y. Anti-proliferative and anti-metastatic potential of curcumin analogue, pentagamavunon-1 (pgv-1), toward highly metastatic breast cancer cells in correlation with ROS generation. Adv. Pharm. Bull., 2019, 9(3), 445-452.
[http://dx.doi.org/10.15171/apb.2019.053] [PMID: 31592109]
[60]
Malaria. 2023. Available from: https://www.who.int/newsroom/questions-and-answers/item/malaria?gclid=Cj0KCQjw9fqnBhDSARIsAHlc QYTghNx3SpzLyJxwIMtld6aUzabul1SCxGDBpXRE4HrCOI53DoPTuu8aAo3JEALw_wcB
[61]
Malaria. 2024. Available from: https://www.who.int/news-room/fact-sheets/detail/malaria
[62]
Hu, Y.Q.; Gao, C.; Zhang, S.; Xu, L.; Xu, Z.; Feng, L.S.; Wu, X.; Zhao, F. Quinoline hybrids and their antiplasmodial and antimalarial activities. Eur. J. Med. Chem., 2017, 139, 22-47.
[http://dx.doi.org/10.1016/j.ejmech.2017.07.061] [PMID: 28800458]
[63]
Shamsujunaidi, R.; Saaidin, A.S.; Aziz, M.H.A.; Mohammat, M.F.; Pungot, N.H. Studies on the synthesis of β-carboline and its derivatives as potential antimalarial drug components. Malays. J. Anal. Sci., 2023, 27(1), 44-53.
[64]
Fan, Y.L.; Cheng, X.W.; Wu, J.B.; Liu, M.; Zhang, F.Z.; Xu, Z.; Feng, L.S. Antiplasmodial and antimalarial activities of quinolone derivatives: An overview. Eur. J. Med. Chem., 2018, 146, 1-14.
[http://dx.doi.org/10.1016/j.ejmech.2018.01.039] [PMID: 29360043]
[65]
Cardiovascular diseases. 2023. Available from: https://www.who.int/health-topics/cardiovascular-diseases#tab=tab_1
[66]
Moris, D.; Spartalis, M.; Spartalis, E.; Karachaliou, G.S.; Karaolanis, G.I.; Tsourouflis, G.; Tsilimigras, D.I.; Tzatzaki, E.; Theocharis, S. The role of reactive oxygen species in the pathophysiology of cardiovascular diseases and the clinical significance of myocardial redox. Ann. Transl. Med., 2017, 5(16), 326.
[http://dx.doi.org/10.21037/atm.2017.06.27] [PMID: 28861423]
[67]
Singh, A.; Kukreti, R.; Saso, L.; Kukreti, S. Oxidative Stress: A key modulator in neurodegenerative diseases. Molecules, 2019, 24(8), 1583.
[http://dx.doi.org/10.3390/molecules24081583] [PMID: 31013638]
[68]
Ceylan, Ş.; Cebeci, Y.U.; Demirbaş, N.; Batur, Ö.Ö.; Özakpınar, Ö.B. Antimicrobial, antioxidant and antiproliferative activities of novel quinolones. ChemistrySelect, 2020, 5(36), 11340-11346.
[http://dx.doi.org/10.1002/slct.202002779]
[69]
How do free radicals affect the body? 2023. Available from: https://www.medicalnewstoday.com/articles/318652
[70]
Scroggs, S.L.P.; Gass, J.T.; Chinnasamy, R.; Widen, S.G.; Azar, S.R.; Rossi, S.L.; Arterburn, J.B.; Vasilakis, N.; Hanley, K.A. Evolution of resistance to fluoroquinolones by dengue virus serotype 4 provides insight into mechanism of action and consequences for viral fitness. Virology, 2021, 552, 94-106.
[http://dx.doi.org/10.1016/j.virol.2020.09.004] [PMID: 33120225]
[71]
Gaillard, T.; Madamet, M.; Tsombeng, F.F.; Dormoi, J.; Pradines, B. Antibiotics in malaria therapy: Which antibiotics except tetracyclines and macrolides may be used against malaria? Malar. J., 2016, 15(1), 556.
[http://dx.doi.org/10.1186/s12936-016-1613-y] [PMID: 27846898]
[72]
Khan, I.A.; Siddiqui, S.; Rehmani, S.; Kazmi, S.U.; Ali, S.H. Fluoroquinolones inhibit HCV by targeting its helicase. Antivir. Ther., 2012, 17(3), 467-476.
[http://dx.doi.org/10.3851/IMP1937] [PMID: 22293206]

Rights & Permissions Print Cite
Article Metrics
18
2
Wayfinder Image
© 2026 Bentham Science Publishers | Privacy Policy